ArticleVeterinary research2021
Experimental evaluation of protection and immunogenicity of Streptococcus suis bacterin-based vaccines formulated with different commercial adjuvants in weaned piglets.
Article in Veterinary research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 57 citations in OpenAlex.
- Development of a cross-protective subunit cocktail vaccine against diverse serotypes of Glaesserella parasuis infection in pigs.Veterinary research · 2026Article
- SSU_RS09155, a virulence-associated gene encoding a putative membrane of unknown function, that is essential for Streptococcus suis serotype 2 virulence.Veterinary research · 2026Article
- Lack of significant impact of deoxynivalenol (DON) on both swine dendritic cell activities and systemic infection caused by a virulent Streptococcus suis serotype 2 strain.Veterinary research · 2026Article
- Maternal antibodies against the immunoglobulin M-degrading enzyme of Streptococcus suis, IdeVeterinary research · 2026Article
- Bayesian network models to assess antimicrobial resistance patterns of Streptococcus suis isolated from swine production systems in the United States between 2014-2021.PLoS computational biology · 2026Article
- Serum IgA and bactericidal immunity against Streptococcus suis serotype 2 is increasing between 2 and 6 weeks of age in a farm with autogenous bacterin vaccination pre-farrowing, while specific maternal IgG is decreasing.Porcine health management · 2026Article
- PRRSV promotes bacterial infection by remodeling actin cytoskeleton and cell membrane proteins.mBio · 2025Article
- Article
- Autogenous Streptococcus suis serotype 1 bacterin: immunogenicities of sow and gilt vaccination protocols.Porcine health management · 2025Article
- Atypical Actinobacillus pleuropneumoniae serotype 12 strains with a higher virulence potential.Veterinary research · 2025Article
- The kinetics of maternal and self-developed Streptococcus suis-specific antibodies.Porcine health management · 2025Article
- Article
- Molecular characterization of Streptococcus suis isolates recovered from diseased pigs in Europe.Veterinary research · 2024Article
- Immune response induced by a Streptococcus suis multi-serotype autogenous vaccine used in sows to protect post-weaned piglets.Veterinary research · 2024Article
- A critical review on experimental Streptococcus suis infection in pigs with a focus on clinical monitoring and refinement strategies.BMC veterinary research · 2023Review
- Vimentin affects inflammation and neutrophil recruitment in airway epithelium during Streptococcus suis serotype 2 infection.Veterinary research · 2023Article
- Immunization of pigs with replication-incompetent adenovirus-vectored African swine fever virus multi-antigens induced humoral immune responses but no protection following contact challenge.Frontiers in veterinary science · 2023Article
- Bacterin Vaccination Provides Insufficient Protection AgainstFrontiers in veterinary science · 2022Article
- Role of Maturation of Lipoproteins in the Pathogenesis of the Infection Caused byMicroorganisms · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Streptococcus suis is an important swine pathogen responsible for economic losses to the swine industry worldwide. There is no effective commercial vaccine against S. suis. The use of autogenous ("bacterin") vaccines to control S. suis outbreaks is a frequent preventive measure in the field, although scientific data on immunogenicity and reduction in mortality and morbidity are scarce. The goal of our study is to experimentally evaluate the immunogenicity and protective efficacy against homologous challenge in weaned piglets of a S. suis serotype 2 bacterin-based vaccine formulated with six different commercial adjuvants (Alhydrogel®, Emulsigen®-D, Quil-A®, Montanide™ ISA 206 VG, Montanide™ ISA 61 VG, and Montanide™ ISA 201 VG). The vaccine formulated with Montanide™ ISA 61 VG induced a significant increase in anti-S. suis antibodies, including both IgG1 and IgG2 subclasses, protected against mortality and significantly reduced morbidity and severity of clinical signs. Vaccines formulated with Montanide ISA 206 VG or Montanide ISA 201 VG also induced a significant increase in anti-S. suis antibodies and showed partial protection and reduction of clinical signs severity. Vaccines formulated with Alhydrogel®, Emulsigen®-D, or Quil-A® induced a low and IgG1-shifted antibody response and failed to protect vaccinated piglets against a homologous challenge. In conclusion, the type of adjuvant used in the vaccine formulation significantly influenced the immune response and efficacy of the vaccine against a homologous challenge.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.